In conclusion, we identify SERT as an immune checkpoint negatively regulating CD8 T cell antitumor immunity through modulating intratumoral T cell-autocrine serotonin and demonstrate the potential of targeting the intratumoral serotonin axis using SSRI antidepressants for T cell-based cancer immunotherapy. Here, CD8A is linked to cancer.